بایگانی برچسب برای: approaches

Cellular.and.Molecular.Approaches.to.[taliem.ir]

Cellular and Molecular Approaches to Regeneration and Repair

The existence of an ischemic stroke “penumbra” was frst hypothesized by Astrup et al. in 1977 by demonstrating that there was a continuum of “threshold of ischemia” measured by electrical failure (potassium gradient) and reduced cerebral blood flow in the baboon cortical grey matter . The gradient indicated an ischemic core, which is now known to be a mass of dead, unrecoverable tissue at the center of the ischemic infarct. The core is surrounded by oligemic tissue, defned as “Oligemia” tissue with reduced blood flow, but function is unaltered, and ischemic tissue with reduced blood flow. The penumbral tissue, is “at risk” of death tissue with altered potassium release, altered electrical failure and dysfunctional. In 1983, Olsen and colleagues demonstrated that an ischemic penumbra also existed in stroke patients; there was differential distribution of blood flow in non-ischemic, ischemic and hyperemic tissues . The Ischemic Penumbra and Time is Penumbra have been reviewed in some detail by Heiss and Donnan , and two main publications in association with receiving the Johann Jacob Wepfer Award . On this occasion, the 40th anniversary of describing the penumbra, we will take a brief look back at the origin of the stroke penumbra, and forward to review current clinically relevant targets that may arrest penumbral recruitment, and the consequences of such detrimental recruitment. We will also briefly discuss the potential need for multiple forms of therapeutic interventions to maximally promote both short and long term recovery in patients.
Clinical Approaches to[taliem.ir]

Clinical Approaches to Hospital Medicine

Heart failure (HF) affects more than 5.7 million adults in the United States and current projections estimate the prevalence of HF will continue to increase. Accounting for more than 1 million admissions annually, HF is the leading cause of hospitalization among the Medicare age group with an overall 1-year mortality rate of 29.6% . In 2013, total cost for HF was estimated to be $30.7 billion with 68% being attributable to direct medical costs. Projections show that by 2030, the total cost of HF will increase almost 127% to $69.7 billion with an estimated $244 spent annually for every US adult . As an emerging issue in hospital care, the hospitalist provider can anticipate a large portion of admissions with either primary or comorbid HF. In this article, we will discuss: • How to recognize HF and classify accordingly • Key treatment modalities • When to consult subspecialists • Risk factors for re-admission and strategies for prevention